Zipsor

Zipsor is a brand name of diclofenac, approved by the FDA in the following formulation(s):

ZIPSOR (diclofenac potassium - capsule; oral)

• 
  Manufacturer: XANODYNE PHARM
  
  Approval date: June 16, 2009
  
  Strength(s): 25MG ^[RLD]

Has a generic version of Zipsor been approved?

No. There is currently no therapeutically equivalent version of Zipsor available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zipsor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Oral liquid compositions
  Patent 6,365,180
  Issued: April 2, 2002
  Inventor(s): Glenn A.; Meyer & Laura A.; Trespidi & Edward S.; Wilson & Christy M.; Clark & Ashok J.; Desai & Frederick D.; Sancilio
  The present invention relates to novel, liquid and semi-solid pharmaceutical compositions which can be administered in liquid form or can be used for preparing capsules containing such pharmaceutical compositions. Also provided are methods of using and processes for preparing the pharmaceutical compositions of the present invention.
  
  Patent expiration dates:
  
  
  • July 15, 2019
    
    ✓ 
    Patent use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
    ✓ 
    Drug product
  
  



• 
  Method of treating post-surgical acute pain
  Patent 7,662,858
  Issued: February 16, 2010
  Inventor(s): Kowalski; Mark M. & Young; James L. & Moore; Keith A.
  Assignee(s): aaiPharma, Inc.
  A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.
  
  Patent expiration dates:
  
  
  • February 24, 2029
    
    ✓ 
    Patent use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
  
  



• 
  Method of treating post-surgical acute pain
  Patent 7,884,095
  Issued: February 8, 2011
  Inventor(s): Kowalski; Mark M. & Young; James L. & Moore; Keith A.
  Assignee(s): aaiPharma Inc.
  A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.
  
  Patent expiration dates:
  
  
  • February 24, 2029
    
    ✓ 
    Patent use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
  
  



• 
  Method of treating post-surgical acute pain
  Patent 7,939,518
  Issued: May 10, 2011
  Inventor(s): Kowalski; Mark M. & Young; James L. & Moore; Keith A.
  Assignee(s): Aaipharma Inc.
  A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.
  
  Patent expiration dates:
  
  
  • February 24, 2029
    
    ✓ 
    Patent use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
  
  



• 
  Method of treating post-surgical acute pain
  Patent 8,110,606
  Issued: February 7, 2012
  Inventor(s): Kowalski; Mark M. & Young; James L. & Moore; Keith A.
  Assignee(s): Aaipharma Services Corp.
  A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.
  
  Patent expiration dates:
  
  
  • February 24, 2029
    
    ✓ 
    Patent use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 16, 2012 - NEW DOSAGE FORM
  
  

See also...

• Zipsor Consumer Information (Drugs.com)
• Zipsor Consumer Information (Wolters Kluwer)
• Zipsor Consumer Information (Cerner Multum)
• Zipsor Advanced Consumer Information (Micromedex)
• Diclofenac Consumer Information (Drugs.com)
• Diclofenac Consumer Information (Wolters Kluwer)
• Diclofenac Enteric-Coated Tablets Consumer Information (Wolters Kluwer)
• Diclofenac Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Diclofenac Immediate-Release Tablets Consumer Information (Wolters Kluwer)
• Diclofenac Potassium Powder Packets Consumer Information (Wolters Kluwer)
• Diclofenac Consumer Information (Cerner Multum)
• Diclofenac Advanced Consumer Information (Micromedex)
• Diclofenac Potassium AHFS DI Monographs (ASHP)
• Diclofenac Sodium AHFS DI Monographs (ASHP)
• Diclofenac epolamine AHFS DI Monographs (ASHP)